Differences in Healthcare Resource Use and Cost by Treatment Choice Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Real-World Analysis of 2016-2021 Claims Data

Cardiovascular Hospitalizations post Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy: A 3-Year Analysis of 5,101 Patients

Symptoms and Complications Significantly Increase the Logistic and Economic Burden of Obstructive Hypertrophic Cardiomyopathy – Results From Medical and Pharmacy Claims Data

Characteristics and Procedural Complications of Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy in the United States

Time from ALS Symptom Onset to Key Disease Milestones for Slow, Intermediate, and Fast Progressors: a Real-World Cross-Sectional Survey

Costs and Healthcare Resource Utilization for Obstructive Hypertrophic Cardiomyopathy With Septal Reduction Therapy

Clinical Profile of Patients Hospitalized for Heart Failure with Severely Reduced Ejection Fraction: From the GWTG-HF Registry

Healthcare Resource Use, Early Benefit, and Cost for North American Patients with HFrEF Most Likely to Benefit from Omecamtiv Mecarbil

Prevalence and Excess Risk of Hospitalization in Heart Failure with Reduced Ejection Fraction

Characterizing Hospitalization as an Outcome Measure in ALS Clinical Trials